135 related articles for article (PubMed ID: 23893067)
21. Bimatoprost - a review.
Patil AJ; Vajaranant TS; Edward DP
Expert Opin Pharmacother; 2009 Nov; 10(16):2759-68. PubMed ID: 19874254
[TBL] [Abstract][Full Text] [Related]
22. The biodisposition and hypertrichotic effects of bimatoprost in mouse skin.
Woodward DF; Tang ES; Attar M; Wang JW
Exp Dermatol; 2013 Feb; 22(2):145-8. PubMed ID: 23278986
[TBL] [Abstract][Full Text] [Related]
23. Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells.
Spada CS; Krauss AH; Woodward DF; Chen J; Protzman CE; Nieves AL; Wheeler LA; Scott DF; Sachs G
Exp Eye Res; 2005 Jan; 80(1):135-45. PubMed ID: 15652534
[TBL] [Abstract][Full Text] [Related]
24. Bimatoprost in the treatment of eyelash hypotrichosis.
Law SK
Clin Ophthalmol; 2010 Apr; 4():349-58. PubMed ID: 20463804
[TBL] [Abstract][Full Text] [Related]
25. Deletion of the gene encoding prostamide/prostaglandin F synthase reveals an important role in regulating intraocular pressure.
Bertrand JA; Woodward DF; Sherwood JM; Spenlehauer A; Silvestri C; Piscitelli F; Marzo VD; Yamazaki M; Sakimura K; Inoue Y; Watanabe K; Overby DR
Prostaglandins Leukot Essent Fatty Acids; 2021 Feb; 165():102235. PubMed ID: 33418484
[TBL] [Abstract][Full Text] [Related]
26. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia.
Barrón-Hernández YL; Tosti A
Expert Opin Investig Drugs; 2017 Apr; 26(4):515-522. PubMed ID: 28264599
[TBL] [Abstract][Full Text] [Related]
27. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence.
Krauss AH; Woodward DF
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S5-11. PubMed ID: 15016556
[TBL] [Abstract][Full Text] [Related]
28. Promising alternative clinical uses of prostaglandin F2α analogs: beyond the eyelashes.
Choi YM; Diehl J; Levins PC
J Am Acad Dermatol; 2015 Apr; 72(4):712-6. PubMed ID: 25601618
[TBL] [Abstract][Full Text] [Related]
29. Flare-up rates with bimatoprost therapy in uveitic glaucoma.
Fortuna E; Cervantes-Castañeda RA; Bhat P; Doctor P; Foster CS
Am J Ophthalmol; 2008 Dec; 146(6):876-82. PubMed ID: 19027422
[TBL] [Abstract][Full Text] [Related]
30. Topical Treatment of Eyebrow Hypotrichosis with Bimatoprost 0.03% Solution: Case Report and Literature Review.
Riahi RR; Cohen PR
Cureus; 2018 May; 10(5):e2666. PubMed ID: 30042917
[TBL] [Abstract][Full Text] [Related]
31. The pharmacology of bimatoprost (Lumigan).
Woodward DF; Krauss AH; Chen J; Lai RK; Spada CS; Burk RM; Andrews SW; Shi L; Liang Y; Kedzie KM; Chen R; Gil DW; Kharlamb A; Archeampong A; Ling J; Madhu C; Ni J; Rix P; Usansky J; Usansky H; Weber A; Welty D; Yang W; Tang-Liu DD; Garst ME; Brar B; Wheeler LA; Kaplan LJ
Surv Ophthalmol; 2001 May; 45 Suppl 4():S337-45. PubMed ID: 11434936
[TBL] [Abstract][Full Text] [Related]
32. Preferential localization of prostamide/prostaglandin F synthase in myelin sheaths of the central nervous system.
Yoshikawa K; Takei S; Hasegawa-Ishii S; Chiba Y; Furukawa A; Kawamura N; Hosokawa M; Woodward DF; Watanabe K; Shimada A
Brain Res; 2011 Jan; 1367():22-32. PubMed ID: 20950588
[TBL] [Abstract][Full Text] [Related]
33. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice.
Crowston JG; Lindsey JD; Morris CA; Wheeler L; Medeiros FA; Weinreb RN
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4571-7. PubMed ID: 16303950
[TBL] [Abstract][Full Text] [Related]
34. Expression and functional evidence of the prostaglandin F2alpha receptor mediating contraction in human umbilical vein.
Errasti AE; del-Rey G; Cesio CE; Souza G; Nowak W; Pelorosso FG; Daray FM; Rothlin RP
Eur J Pharmacol; 2009 May; 610(1-3):68-74. PubMed ID: 19289115
[TBL] [Abstract][Full Text] [Related]
35. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue.
Hellberg MR; Ke TL; Haggard K; Klimko PG; Dean TR; Graff G
J Ocul Pharmacol Ther; 2003 Apr; 19(2):97-103. PubMed ID: 12804054
[TBL] [Abstract][Full Text] [Related]
36. Prostamide F(2) α receptor antagonism combined with inhibition of FAAH may block the pro-inflammatory mediators formed following selective FAAH inhibition.
Ligresti A; Martos J; Wang J; Guida F; Allarà M; Palmieri V; Luongo L; Woodward D; Di Marzo V
Br J Pharmacol; 2014 Mar; 171(6):1408-19. PubMed ID: 24102214
[TBL] [Abstract][Full Text] [Related]
37. Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides.
Smid SD
Clin Ophthalmol; 2009; 3():663-70. PubMed ID: 20054414
[TBL] [Abstract][Full Text] [Related]
38. Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma.
Berenson KL; Kymes S; Hollander DA; Fiscella R; Burk C; Patel VD
Am J Manag Care; 2011 Sep; 17(9):e365-74. PubMed ID: 21902444
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis.
Chanasumon N; Sriphojanart T; Suchonwanit P
Drug Des Devel Ther; 2018; 12():365-372. PubMed ID: 29503529
[TBL] [Abstract][Full Text] [Related]
40. Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study.
Konstas AG; Holló G; Irkec M; Tsironi S; Durukan I; Goldenfeld M; Melamed S
Br J Ophthalmol; 2007 Jun; 91(6):757-60. PubMed ID: 17124241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
